How 'molecular glue' redirects a cancer-driving protein to activate cell death
Read Full Article on Health Medicine Network
Health Medicine Network covers TCIP3, the two-headed molecule from Stanford Medicine, MD Anderson, and Deep Origin that turns BCL6, a lymphoma driver, into a trigger for cell death and cleared aggressive tumors in mice within 11 days.
Health Medicine Network covers TCIP3, a two-headed molecule developed by Stanford Medicine researchers, with contributions from MD Anderson Cancer Center and Deep Origin, described as an AI-powered drug discovery platform. Rather than blocking BCL6, the protein that drives diffuse large B-cell lymphoma, TCIP3 physically links it to P300 and CBP, which activate cell death genes while silencing growth signals. In mice with aggressive lymphoma, twice-daily treatment eliminated tumors within 11 days with no apparent toxicity.
X-ray crystallography showed TCIP3 acting as a “molecular glue” that anchors the proteins together, forming unplanned chemical contacts that strengthen the effect beyond what the design anticipated. The study, published in Cell, suggests the chemically induced proximity approach could extend to other cancer-driving proteins and potentially to autoimmune diseases such as rheumatoid arthritis. Further chemical refinement and animal testing are needed before human trials.
The underlying study is available in our resource library: A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.
